a n n ua l r e p o r t 2010
Prosensa will share operational knowledge and this will benefit the development of both companies.” Richard Holslag: “Mibiton is a very attractive fund for young and start-up companies. This revolving fund is a very welcome instrument for Life Sciences companies. Mibiton understands the Life Sciences business and that is very important.”
Platenburg: “ISA is the third new Life Sciences company that I’ve set up. However, I won’t do this again under the present circumstances. The burden is too heavy, there are too many regulations and there is too much stress.” Holslag: “Mibiton is the favourable exception. We enjoy working with Mibiton because we know that the Mibiton formula with its revolving fund works well for the Life Sciences sector.”
Gerard Platenburg: “This is the way Life Sciences investors should work: fast and accurate.” Platenburg and Holslag pledge for a more innovative climate for Life Sciences in the Netherlands.
brigitte warner - burm , prosensa
“Prosensa, Proxy and Mibiton are three of a kind” Prosensa in Leiden (NL) is a biopharmaceutical company focused on developing treatments for Duchenne Muscular Dystrophy (DMD). At the end of 2009 Prosensa entered into a worldwide collaboration with GlaxoSmithKline for the development and commercialization of part of its RNAbased therapeutics for DMD. Both parties are involved in a Phase III study which started in 2010.
operates as an independent quality control laboratory and is validated for the international Life Sciences and pharmaceutical industry. Proxy Laboratories offered the necessary GLP and GMP-expertise and Mibiton provided the valuable analytical equipment in the form of an LCMS facility which can be used for GLP analyses. The equipment is located at Proxy Laboratories.
Brigitte Wanner-Burm, Manager Quality Control and Analytical Development of Prosensa: “When Prosensa reached the clinical stage it could no longer rely on the analytical methods of the research laboratory. We had to develop validated methods in validated laboratories, and therefore had to invest in facilities with a GLP en GMP certification. As this is very expensive for a small company, we sought the expertise of Proxy Laboratories, which
Mibiton is a unique fund and its revolving nature stimulates entrepreneurship. Without Mibiton it is very difficult for small companies to obtain financing for facilities, especially companies in the Life Sciences sector. We are extremely pleased with both the Mibiton investment and the collaboration with Proxy, which have given us a flying start in the world of GLP and GMP.”
Brigitte Warner-Burm, Manager Quality Control and Analytical Development of Prosensa
15